Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Biotechnology

Healthcare
$20.58 -3.08%

-$0.74 today

Market cap
$302.08M
Beta
1.38
P/E (TTM)
-15.6
EPS (TTM)
-$1.49
52W Low $7.78High $34.10

Volume 0.71M

Average 0.14M

GLSI EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Greenwich LifeSciences, Inc.NASDAQ: GLSI

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$5.66M, compared with -$2.74M a year earlier. Trailing-twelve-month EBITDA was -$21.76M.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -11.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.66M+28.6% QoQ
Last fiscal yearDec 2025
-$19.36M-11.2% YoY
LTMMar 2026
-$21.76M-35.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-106.2%+100.0%+206.2 pp
1 year-11.2%+100.0%+111.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(19.36M) USD
Year-over-year change
-11.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How GLSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.5% is the 5th highest of 9, against a peer median of -43.1%.
GLSI Competitors
EBITDA for GLSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$127.04M USD+256.7%—102.6%
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$19.31M USD+41.5%——
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026-$21.76M USD-35.5%——
HURATuHURA Biosciences, Inc.LTM Mar 2026-$30.19M USD-68.1%——
IMMXImmix Biopharma, Inc.LTM Mar 2026-$34.56M USD-66.8%——
ONCYOncolytics Biotech Inc.LTM Mar 2026-CA$36.08M CAD-19.5%——
SEERSeer, Inc.LTM Mar 2026-$64.35M USD+18.9%—427.9%
IRDOpus Genetics, Inc.LTM Mar 2026-$104.73M USD-226.0%—874.0%
SRZNSurrozen, Inc.LTM Mar 2026-$342.25M USD-325.9%—4567.0%
Peer median (excluding GLSI) —-43.1%—650.9%

Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue3.61K3.61K3.61K3.61K1.78K
Gross Profit(3.61K)(3.61K)(3.61K)(3.61K)(1.78K)
Gross Margin—————
Research & Development3.56M6.48M7.7M15.48M17.22M
Selling, General & Admin1.04M1.56M1.63M2.15M2.23M
Operating Expenses4.59M8.04M9.32M17.63M19.45M
Depreciation & Amortization3.61K3.61K3.61K3.61K1.78K
EBITDA(4.57M)(7.82M)(8.89M)(17.41M)(19.36M)
EBITDA Margin—————
Operating Income(4.6M)(8.04M)(9.33M)(17.64M)(19.45M)
Operating Margin—————
Interest Income27.37K215.02K436.06K223.01K89.7K
Interest Expense00000
Other Income / Expenses27.37K215.02K436.06K223.01K89.7K
Income Before Tax(4.57M)(7.83M)(8.89M)(17.41M)(19.36M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(4.57M)(7.83M)(8.89M)(17.41M)(19.36M)
Net Margin—————
EPS (Basic)(0.35)(0.61)(0.69)(1.21)(1.43)
EPS (Diluted)(0.35)(0.61)(0.69)(1.21)(1.43)
Weighted Avg Shares12.94M12.91M12.85M13.01M13.53M
Weighted Avg Shares (Diluted)12.94M12.91M12.85M13.01M13.53M

Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Intrinsic Alpha fair value

Locked

Current Price

$20.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.